EEF1A1 and metastatic malignant neoplasm: As further preclinical and clinical studies elucidate the safety, efficacy, and optimal applications of metarrestin-based compounds, which also include PROTAC degraders, these agents may emerge as a new class of precision therapeutics for treating eEF1A-driven malignancies and addressing the persistent challenge of metastatic cancer.